Calu-1 is a non-small-cell lung cancer (NSCLC) cell line that grows in adherent culture and displays epithelial morphology. These cells express wildtype LKB1, wildtype EGFR, and mutant K-Ras (G12C). In addition, they lack expression of both p53 (homozygous deletion) and FHIT (Fragile Histidine Triad) tumor-suppressor proteins. The Calu-1 cells are intrinsically resistant to erlotinib, an EGFR tyrosine kinase inhibitor used in the treatment of NSCLC patients. These cells are capable of forming tumors in immunocompromised mice.
This cell line was established in 1971 from a metastatic site (pleura) in a 47-year-old Caucasian male with epidermoid carcinoma of the lung.
- Germain Trempe, formerly at Sloan Kettering Institute, Memorial Sloan Kettering
- Jorgen Fogh, PhD, formerly at Sloan Kettering Institute, Memorial Sloan Kettering
- Fogh J et al. (1977) One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. Journal of the National Cancer Institute 59: 221-226 (PubMed ID: 327080)
- Cavazzoni A et al. (2007) Effect of inducible FHIT and p53 expression in the Calu-1 lung cancer cell line. Cancer Letters 246: 69-81 (PubMed ID: 16616810)
This cell line may be licensed nonexclusively for research or commercial purposes.
- Express License: For internal research purposes by a for-profit entity: Fill out MSK’s Core Express License; see here for links to the online fillable Core Express License, as well as a PDF version. For detailed guidance on how to fill out this webform, see here. Please note: In order to streamline and expedite the licensing of select MSK cell lines, the terms of this non-exclusive license are non-negotiable. This license is only available for select cell lines, including this one. Once this license has been executed by MSK, you will receive a signed copy and payment instructions; all payments up to $10,000 must be made by credit card.
- Commercial License: Contact MSK’s Tangible Research Materials team at [email protected].
- For non-licensing requests from academic-research institutions: Contact MSK’s Antibody & Bioresource Core Facility at [email protected].